// App-Quantinova.ai

CT220 : Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Researchers

Presenter

  • Leora Horn

Principal Investigators

  • Aaron S. Mansfield

  • Tony Mok

  • Arnaud Scherpereel

  • Niels Reinmuth

  • Marina Chiara Garassino

  • Javier De Castro Carpeno

  • Raffaele Califano

  • Makoto Nishio

  • Francisco Orlandi

  • Jorge Arturo Alatorre Alexander

  • Ticiana Leal

  • Ying Cheng

  • Jong-Seok Lee

  • Sivuonthanh Lam

  • Mark McCleland

  • Yu Deng

  • See Phan

  • Martin Reck

Medical Centers

  • Vanderbilt University, Nashville, TN

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • State Key Laboratory for Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Department of Pulmonary and Thoracic Oncology, Lille University Hospital, Lille, France

  • Thoracic Oncology, Asklepios Lung Clinic, Munich-Gauting, Germany

  • Medical Oncology, Istituto Nazionale dei Tumori, Milano, Italy

  • Hospital Universitario La Paz, Madrid, Spain

  • Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Instituto Nacional del Tórax, Prosalud Oncología, Santiago, Chile

  • Health Pharma Professional Research, Mexico City/MX

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Jilin Cancer Hospital, Jilin, China

  • Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Democratic People's Republic of Korea

  • Genentech, Inc., South San Francisico, CA

  • LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

Locations

  • United States

  • Hong Kong

  • France

  • Germany

  • Italy

  • Spain

  • United Kingdom

  • Japan

  • Chile

  • Mexico

  • China

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Carboplatin

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • I/II

Study Id's

  • NCT02763579

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved